{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:08:16Z","timestamp":1772168896488,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.14970.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000}}],"reference-count":33,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>\n                    <ns4:bold>Background:<\/ns4:bold>\n                    Adverse drug reactions (ADRs) are a major cause of hospital admissions, prolonged hospital stays, morbidity, and drug-related mortality. In this study, we sought to identify the most frequently reported medications and associated side effects in adolescent-aged patients in an effort to prioritize clinical pharmacology consultation efforts for hospitals seeking to improve patient safety. \u00a0\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Methods:<\/ns4:bold>\n                    Quarterly reported data were obtained from the United States Food and Drug Administration Adverse Events Reporting System (FAERS) from the third quarter of 2014 and ending in the third quarter of 2017. We then used the GeneCards database to map the pharmacogenomic biomarkers associated with the most reported FAERS drugs. Data homogenization and statistics analysis were all conducted in R for statistical programming.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Results:<\/ns4:bold>\n                    We identified risperidone (10.64%) as the compound with the most reported ADRs from all reported cases. Males represented 90.1% of reported risperidone cases with gynecomastia being the most reported ADR. Ibuprofen OR=188 (95% CI, 105.00 \u2013 335.00) and quetiapine fumarate OR=116 (95% CI, 48.40 \u2013 278.00) were associated with the highest odds of completed suicide in teenagers. Ondansetron hydrochloride OR=7.12 (95% CI, 1.59 \u2013 31.9) resulted in the highest odds of pneumothorax. Lastly, olanzapine (8.96%) represented the compound with the most reported drug-drug interactions cases, while valproic acid OR=221 (95% CI, 93.900 \u2013 522.00) was associated with the highest odds of drug-drug interactions.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Conclusion:<\/ns4:bold>\n                    Despite any data limitations, physicians prescribing risperidone in males should be aware of the high rates of adverse drug events and an alternative psychotropic should be considered in male patients. Further, patients with a history of pneumothorax or genetically predisposed to pneumothorax should be considered for an alternative antiemetic to ondansetron hydrochloride, due to increased odds associated with the drug and adverse event.\n                  <\/ns4:p>","DOI":"10.12688\/f1000research.14970.2","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T11:25:10Z","timestamp":1534245910000},"page":"677","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers"],"prefix":"10.12688","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-5454","authenticated-orcid":false,"given":"Andy R.","family":"Eugene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Eugene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"161-169","DOI":"10.1111\/j.1365-2125.2011.04079.x","article-title":"What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists.","volume":"73","author":"J Aronson","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.","volume":"11","author":"R B\u00f6hm","year":"2016","journal-title":"PLoS One."},{"key":"ref-2","article-title":"Precision Psychiatry\u2014 Will Genomic Medicine Lead the Way?","author":"D Boorstein","year":"2018","journal-title":"JAMA Psychiatry."},{"key":"ref-3","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12526","article-title":"Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years.","volume":"11","author":"A Borobia","year":"2018","journal-title":"Clin Transl Sci."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"265-273","DOI":"10.1007\/s13181-015-0472-1","article-title":"Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome.","volume":"11","author":"K Burkhart","year":"2015","journal-title":"J Med Toxicol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"1321-8","DOI":"10.1080\/14740338.2016.1221921","article-title":"Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.","volume":"15","author":"K Cliff-Eribo","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"e4439","DOI":"10.1371\/journal.pone.0004439","article-title":"Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes.","volume":"4","author":"E Davies","year":"2009","journal-title":"PLoS One."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"e0130399","DOI":"10.1371\/journal.pone.0130399","article-title":"Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.","volume":"10","author":"S de Bie","year":"2015","journal-title":"PLoS One."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"63-66","DOI":"10.1002\/cpt.347","article-title":"Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.","volume":"100","author":"M Eadon","year":"2016","journal-title":"Clin Pharmacol Ther."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"843-851","DOI":"10.1007\/s00228-018-2432-6","article-title":"Clinical pharmacology in Stockholm 50 years-report from the jubilee symposium.","volume":"74","author":"M Eichelbaum","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"key":"ref-8","article-title":"Methodology Updates for Best Hospitals 2017\u201318.","author":"B Harder","year":"2017","journal-title":"U.S. News & World Report."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"195-235","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.","volume":"44","author":"C Hiemke","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1541-1543","DOI":"10.1007\/s00228-016-2141-y","article-title":"Consulting clinical pharmacologist about treatment of inpatients in a tertiary hospital in Serbia.","volume":"72","author":"S Jankovi\u0107","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"918-26","DOI":"10.1002\/phar.1455","article-title":"Drugs associated with adverse events in children and adolescents.","volume":"34","author":"W Lee","year":"2014","journal-title":"Pharmacotherapy."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"134-137","DOI":"10.1038\/sj.clpt.6100028","article-title":"American Board of Clinical Pharmacology fellowship training and certification in clinical pharmacology: educational value and future needs for the discipline.","volume":"81","author":"L Lewis","year":"2007","journal-title":"Clin Pharmacol Ther."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"225-236","DOI":"10.1016\/j.atherosclerosis.2016.08.034","article-title":"Implementing genomics and pharmacogenomics in the clinic: The National Human Genome Research Institute\u2019s genomic medicine portfolio.","volume":"253","author":"T Manolio","year":"2016","journal-title":"Atherosclerosis."},{"key":"ref-13","first-page":"69-74","article-title":"Genetics and Genomics in Clinical Practice: The Views of Wisconsin Physicians.","volume":"116","author":"M McCauley","year":"2017","journal-title":"WMJ."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"542-552","DOI":"10.1111\/bcp.13471","article-title":"Drug-related deaths in hospital inpatients: A retrospective cohort study.","volume":"84","author":"E Montan\u00e9","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"1-7","DOI":"10.2165\/00002018-200124010-00001","article-title":"The role of the clinical pharmacologist in the management of adverse drug reactions.","volume":"24","author":"N Moore","year":"2001","journal-title":"Drug Saf."},{"key":"ref-16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.","author":"Y Oshima","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"462-476","DOI":"10.1111\/bcp.13480","article-title":"Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.","volume":"84","author":"T Polasek","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"ref-18","article-title":"R: A Language and Environment for Statistical Computing","year":"2015"},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"482-9","DOI":"10.1038\/clpt.2014.137","article-title":"Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems.","volume":"96","author":"L Rasmussen-Torvik","year":"2014","journal-title":"Clin Pharmacol Ther."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"54-59","DOI":"10.1016\/j.jval.2016.08.727","article-title":"Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.","volume":"20","author":"M Rosenman","year":"2017","journal-title":"Value Health."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"225-235","DOI":"10.1007\/s40264-014-0141-3","article-title":"Self-medication with over-the-counter and prescribed drugs causing adverse-drug-reaction-related hospital admissions: Results of a prospective, long-term multi-centre study.","volume":"37","author":"S Schmiedl","year":"2014","journal-title":"Drug Saf."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"169-75","DOI":"10.1345\/aph.1P592","article-title":"Adverse drug reaction deaths reported in United States vital statistics, 1999-2006.","volume":"46","author":"G Shepherd","year":"2012","journal-title":"Ann Pharmacother."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1.30.1-1.30.33","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses.","volume":"54","author":"G Stelzer","year":"2016","journal-title":"Curr Protoc Bioinformatics."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1-27","DOI":"10.1007\/s40262-018-0650-9","article-title":"Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.","author":"F Storelli","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"341-358","DOI":"10.1002\/cpt.725","article-title":"Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002\/cpt.602).","volume":"102","author":"C van der Wouden","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1711-1722","DOI":"10.1016\/j.mayocp.2017.09.001","article-title":"Pharmacogenomics: Precision Medicine and Drug Response.","volume":"92","author":"R Weinshilboum","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"ref-26","article-title":"GeneCards. v4.1 Build 30","year":"2016"},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"329-41","DOI":"10.1007\/s10928-012-9253-5","article-title":"Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.","volume":"39","author":"H Yoo","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"159-63","DOI":"10.1007\/s00228-014-1787-6","article-title":"Clinical pharmacology in Russia-historical development and current state.","volume":"71","author":"K Zagorodnikova Goryachkina","year":"2015","journal-title":"Eur J Clin Pharmacol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-677\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-677\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-677\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T15:32:18Z","timestamp":1544110338000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-677\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":33,"URL":"https:\/\/doi.org\/10.12688\/f1000research.14970.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.17384.r37199","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17384.r37198","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17384.r37198","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.17384.r37199","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,14]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-677\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.17384.r37198, Antonio J. Carcas, Clinical Pharmacology Department, IdiPAZ, La Paz University Hospital, School of Medicine, Autonomous University of Madrid, Madrid, Spain, 22 Aug 2018, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/7-677\/v2#referee-response-37198","order":0,"name":"referee-response-37198","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17384.r37199, Daniel D Hawcutt, Department of Women's and Children's Health, University of Liverpool, Liverpool, UK, 14 Sep 2018, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/7-677\/v2#referee-response-37199","order":1,"name":"referee-response-37199","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}